IDEAYA Biosciences and Servier reported positive topline results from the Phase 2/3 registrational OptimUM-02 trial of darovasertib plus crizotinib. The readout is an important clinical milestone for the oncology program and supports the drug combination’s regulatory trajectory. The news is likely supportive for IDYA shares as it advances a late-stage asset with registrational potential.
IDEAYA Biosciences and Servier reported positive topline results from the Phase 2/3 registrational OptimUM-02 trial of darovasertib plus crizotinib. The readout is an important clinical milestone for the oncology program and supports the drug combination’s regulatory trajectory. The news is likely supportive for IDYA shares as it advances a late-stage asset with registrational potential.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.70
Ticker Sentiment
